Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial

被引：0
|
作者：
Jin, Y. [1 ]
Yu, X. [1 ]
Fan, Y. [1 ]
He, X. Q. [1 ]
Lin, C. [1 ]
Hong, W. [1 ]
Gu, C. [1 ]
机构：
[1] Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
497P
引用
收藏
页码：S1656 / S1657
页数：2
相关论文
共 50 条
  • [1] A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC
    Xiong, J.
    Li, J.
    Deng, J.
    Zhang, W.
    Wang, H.
    Zeng, L.
    Shi, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S675 - S676
  • [2] DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
    Li, H-S.
    Xu, H.
    Duan, J.
    Wang, Z.
    Zhong, J.
    Cui, Y-Y.
    Fang, Q.
    Lei, S-Y.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2023, 34
  • [3] Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
    Fan, Y.
    Chen, K.
    Xu, Y.
    Huang, Z.
    Hong, W.
    Li, H.
    Xie, F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S352 - S352
  • [4] Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II study
    Wang, Z.
    Qin, B.
    Ye, C.
    Wang, M.
    Yuan, L.
    Yao, H.
    Jiao, X.
    Liu, K.
    Sun, L.
    Dai, W.
    Ling, Y.
    Wu, Y.
    Chen, S.
    Zhang, Y.
    Shi, D.
    Duan, X.
    Zhong, X.
    He, X.
    Zhai, W.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1433 - S1433
  • [5] Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
    Laoguo, Shi-xue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, GuangZhi
    Ma, Fuchao
    Peng, Tao
    Zeng, Zhiming
    Ma, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 576 - 576
  • [6] First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
    Shi, H.
    Zhu, H.
    Feng, Y.
    Liu, Y.
    Xing, P.
    Hu, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1132 - S1133
  • [7] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
    Wang, J.
    Wu, T.
    Hong, Y-G.
    Luo, S-X.
    Li, N.
    Guo, Y-Z.
    Cheng, Y-F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
  • [8] Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints
    Han, B.
    Chu, T.
    Zhong, R.
    Zhong, H.
    Zhang, B.
    Zhang, W.
    Shi, C.
    Qian, J.
    Zhang, Y.
    Chang, Q.
    Zhang, X.
    Dong, Y.
    Teng, J.
    Gao, Z.
    Qiang, H.
    Nie, W.
    Zhao, Y.
    Han, Y.
    Chen, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S119 - S119
  • [9] Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
    Wang, Zhi-ming
    Zhuang, Rong-yuan
    Guo, Xi
    Zhang, Chen-lu
    You, Yang
    Chen, Li-sha
    Liu, Wen-shuai
    Zhang, Yong
    Luo, Rong-kui
    Hou, Ying-yong
    Lu, Wei-qi
    Zhou, Yu-hong
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5290 - 5296
  • [10] Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): A single-centre, single-arm, phase II trial
    Liu, Z.
    Liu, M.
    Xu, J.
    Fu, H.
    Zhu, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S1038 - S1038
12345